Your numbers look great for somebody on treatment, couldn't ask for anything any better at week 7. Keep an eye on your HGB but at 10.7 your still good........... Best to you.
Thank you. Hard to watch them drop as I'm sure everyone knows this. Two weeks ago that 10.7 was 11.9 Hangin in there...
If it makes you feel any better, early-onset anemia is a good sign that your body is getting enough medicine to remain SVR, after treatment.
Thank you so much for your post...Now I hadn't looked at it that way...hmmmm
Yeah, lots of times, people who have a hard time clearing this virus, will also notice that their HGB isn't going down, also. One poster on here told me his Doctor upped his Ribavirin , until it gave him (hemolytic) anemic, because he wasn't able to clear the virus, until the Riba knocked his HGB down....I will try to find an article on it for you
Here's an article, from a GastroJournal ~
Background & Aims
Hepatitis C virus (HCV) treatment is frequently complicated by anemia from ribavirin (RBV)-related hemolysis and peginterferon-alfa (PEG-IFN)-related bone marrow suppression. We investigated the relationships among treatment outcomes, anemia, and their management with RBV dose reduction and/or erythropoiesis-stimulating agents (ESAs).
We analyzed data from a trial conducted at 118 United States academic and community centers in treatment-naïve patients with HCV genotype 1. Patients were treated for as many as 48 weeks with 1 of 3 PEG-IFN/RBV regimens. ESAs were permitted for anemic patients (hemoglobin [Hb] 3 g/dL, 43.7%; ≤3 g/dL, 29.9% (P < .001). Anemia occurred in 865 patients (28.6%); 449 of these (51.9%) used ESAs. In patients with early-onset anemia (≤ 8 weeks of treatment), ESAs were associated with higher SVR rate (45.0% vs 25.9%; P < .001) and reduced discontinuation of treatment because of adverse events (12.6% vs 30.1%, P < .001). ESAs did not affect SVR or discontinuation rates among patients with late-stage anemia.
Among HCV genotype 1-infected patients treated with PEG-IFN/RBV, anemia was associated with higher rates of SVR. The effect of ESAs varied by time to anemia; patients with early-onset anemia had higher rates of SVR with ESA use, whereas no effect was observed in those with late-onset anemia. Prospective trials are needed to assess the role of ESAs in HCV treatment.